Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

✍ Scribed by M. Campone; N. Isambert; E. Bourbouloux; S. Maury; P. Monin-Baroille; J. Berille; P. Fumoleau

• Book ID: 118297104
• Publisher: Springer
• Year: 2006
• Tongue: English
• Weight: 274 KB
• Volume: 59
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-006-0349-8